Medigene presents at five upcoming conferences

Planegg – Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming conferences:

BIO International Convention
Date: 4 – 7 June 2018
Location: Boston, USA

Jefferies Global Healthcare Conference
Date: 5 – 8 June 2018
Locations: New York, USA
Prof. Dolores Schendel, CEO and CSO of Medigene AG, is invited to hold a company presentation on 7 June.

Biomarkers and Immuno-Oncology World Congress
Date: 11 – 13 June 2018
Location: Boston, USA

3rd Annual Oncology Day by Bryan Garnier & Co.
Date: 13 June 2018
Location: Paris, France
Prof. Dolores Schendel, CEO and CSO of Medigene AG, is invited to hold a company presentation.

23rd Congress of the European Hematology Association (EHA)
Date: 14 – 15 June 2018
Location: Stockholm, Sweden

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,

This site is registered on as a development site.